Potencial alelopático de catequinas de Tachigali myrmecophyla (leguminosae)

Two compounds, (+)-catechin and epicatechin, were isolated from leaves of T. myrmecophyla, using chromatographic techniques. The structural identification was carried out on the basis of ¹H and 13C NMR spectral data and comparison with literature data. The compounds (+)-catechin and epicatechin were submitted to germination inhibition and radicle and hypocotyl growth assays. Results showed some significant activities confirming the initial hypothesis about allelopathic properties of that plant

Supercritical CO2 extraction of ucuúba (Virola surinamensis) seed oil: global yield, kinetic data, fatty acid profile, and antimicrobial activities

CAPES-Brazil for the master's scholarship (process: 1214046/2013-4)Federal University of Pará. Faculty of Chemical Engineering. Belém, PA, Brazil.Federal University of Pará. Faculty of Food Engineering. ABEX (Laboratory of Extraction). Belém, PA, Brazil.Federal University of Pará. Faculty of Food Engineering. ABEX (Laboratory of Extraction). Belém, PA, Brazil.Federal University of Pará. Faculty of Chemical Engineering. Belém, PA, Brazil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Ananindeua, PA, Brasil.Federal University of Pará. Graduate Program in Chemistry. Belém, PA, Brazil.Federal University of Pará. Graduate Program in Chemistry. Belém, PA, Brazil.Federal University of Pará. Faculty of Food Engineering. ABEX (Laboratory of Extraction). Belém, PA, Brazil.Virola surinamensis is an abundant floodplain tree, popularly known as ucuúba, that grows in the Amazon. In this study, ucuúba seed oil was obtained by supercritical fluid extraction under different operating conditions, as well as Soxhlet extraction. The operating conditions for supercritical extraction were an extraction temperature of 40, 60, or 80 °C, a pressure of 350 bar, and a CO2 mass flow of 7.9 × 10−5 kg/s. The supercritical extraction curves were fitted to mass transfer models, and the fatty acid profiles of the extracts were determined by gas chromatography. The antimicrobial activity was assessed against Candida albicans, Staphylococcus aureus, and Escherichia coli. The highest yield obtained using supercritical CO2 was 64.39% and the lowest was 59.21%. The phytochemical analysis showed the presence of steroids, terpenes, coumarins, and phenolic compounds. All ucuúba oil samples showed antioxidant activity. Regarding the antimicrobial activity, ucuúba oil only showed activity against S. aureus

Pellucidin A promotes antinociceptive activity by peripheral mechanisms inhibiting COX-2 and NOS: In vivo and in silico study.

Peperomia pellucida (PP) belongs to the Peperomia genus, which has a pantropic distribution. PP is used to treat a wide range of symptoms and diseases, such as pain, inflammation, and hypertension. Intriguingly, PP extract is used by different tropical countries for its anti-inflammatory and antinociceptive effects. In fact, these outcomes have been shown in animal models, though the exact bioactive products of PP that exert such results are yet to be discovered. To determine and elucidate the mechanism of action of one of these compounds, we evaluated the antinociceptive effect of the novel dimeric ArC2 compound, Pellucidin A by using in vivo and in silico models. Animals were then subjected to chemical, biphasic and thermal models of pain. Pellucidin A induced an antinociceptive effect against chemical-induced pain in mice, demonstrated by the decrease of the number of writhes, reaching a reduction of 43% and 65% in animals treated with 1 and 5 mg/kg of Pellucidin A, respectively. In the biphasic response (central and peripheral), animals treated with Pellucidin A showed a significant reduction of the licking time exclusively during the second phase (inflammatory phase). In the hot-plate test, Pellucidin A did not have any impact on the latency time of the treated animals. Moreover, in vivo and in silico results show that Pellucidin A's mechanism of action in the inflammatory pain occurs most likely through interaction with the nitric oxide (NO) pathway. Our results demonstrate that the antinociceptive activities of Pellucidin A operate under mechanism(s) of peripheral action, involving inflammatory mediators. This work provides insightful novel evidence of the biological properties of Pellucidin A, and leads to a better understanding of its mechanism of action, pointing to potential pharmacological use

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN